Interstitial laser therapy of benign prostatic hyperplasia

Area of Science:

• Urology
• Minimally Invasive Surgery
• Laser Therapeutics

Background:

• Benign prostatic enlargement (BPE) causes bladder outlet obstruction and lower urinary tract symptoms (LUTS).
• Traditional treatments like transurethral resection of the prostate (TURP) carry significant morbidity.
• Interstitial laser coagulation (ILC) offers a less invasive approach to BPE treatment.

Purpose of the Study:

• To evaluate the effectiveness of ILC in reducing prostate volume and improving LUTS.
• To assess the safety and long-term outcomes of ILC for BPE.
• To compare ILC with established BPE treatments.

Main Methods:

• ILC utilizes Nd:YAG or diode lasers with specialized applicators to induce coagulation necrosis within the prostate adenoma.
• Applicators allow precise tissue coagulation, preserving surrounding structures like the urethra.
• Study designs included single-armed and randomized trials with outcome measures like AUA score, peak flow rate, and pressure-flow studies.

Main Results:

• ILC demonstrated significant improvements in AUA scores, peak flow rates, and reduced residual urine and prostate volumes.
• Pressure-flow studies confirmed decreased intravesical/detrusor pressure, urethral opening pressure, and urethral resistance.
• Long-term follow-up (up to 3 years) in 394 patients showed sustained efficacy, suitable for large prostates and highly obstructive cases.

Conclusions:

• ILC is an effective treatment for benign prostatic enlargement, offering significant symptom relief and prostate volume reduction.
• The procedure presents a viable alternative to TURP with lower morbidity, though it may require postoperative catheterization.
• ILC can be performed under local anesthesia without hospitalization, enhancing patient convenience.